Ondansetron

Generic Name
Ondansetron
Brand Names
Zofran, Zuplenz
Drug Type
Small Molecule
Chemical Formula
C18H19N3O
CAS Number
99614-02-5
Unique Ingredient Identifier
4AF302ESOS
Background

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis.

The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.

Indication

In the adult patient population:

i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and

- the prevention and treatment of postoperative nausea and vomiting

ii) intravenously administered ondansetron injection formulations are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and

- the prevention and treatment of postoperative nausea and vomiting

In the pediatric (4-18 years of age) patient population:

i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting,

ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger,

iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and

iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting

In the geriatric (>65 years of age) patient population:

i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and

ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population

Associated Conditions
Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
Associated Therapies
-

Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-08-17
Last Posted Date
2016-04-06
Lead Sponsor
United States Naval Medical Center, San Diego
Target Recruit Count
36
Registration Number
NCT01668069
Locations
🇺🇸

Naval Medical Center, San Diego, San Diego, California, United States

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

First Posted Date
2012-07-13
Last Posted Date
2013-11-07
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
40
Registration Number
NCT01640340
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

Randomized Double Blind Placebo Control Study in Patients with Schizophrenia

First Posted Date
2012-05-18
Last Posted Date
2024-12-10
Lead Sponsor
Pakistan Institute of Living and Learning
Target Recruit Count
303
Registration Number
NCT01602029
Locations
🇵🇰

Dow university of Health Sciences, Karachi, Sind, Pakistan

🇵🇰

Karwan e hayat, Karachi, Pakistan

🇵🇰

Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

First Posted Date
2012-04-05
Last Posted Date
2014-01-24
Lead Sponsor
Halozyme Therapeutics
Target Recruit Count
12
Registration Number
NCT01572012
Locations
🇺🇸

Icon Development Solutions, San Antonio, Texas, United States

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

First Posted Date
2012-03-09
Last Posted Date
2019-01-07
Lead Sponsor
Stanford University
Target Recruit Count
133
Registration Number
NCT01549652
Locations
🇺🇸

Stanford University, Stanford, California, United States

Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy

First Posted Date
2012-03-05
Last Posted Date
2012-07-31
Lead Sponsor
Prince of Songkla University
Target Recruit Count
340
Registration Number
NCT01543945
Locations
🇹🇭

Anesthesiology Department, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

First Posted Date
2012-02-22
Last Posted Date
2012-10-03
Lead Sponsor
Hallym University Medical Center
Target Recruit Count
338
Registration Number
NCT01536691
Locations
🇰🇷

Hyo Jung Kim, Anyang, Gyeonggi-do, Korea, Republic of

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

First Posted Date
2012-02-22
Last Posted Date
2021-06-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
76
Registration Number
NCT01536392
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Lyndon B. Johnson General Hospital, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath